Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: Killing 2 birds with 1 stone

Transplantation Reviews

Volumn 25, Issue 4, 2011, Pages 145-153

  Haidinger, Michael ^a   Werzowa, Johannes ^a   Weichhart, Thomas ^a   Säemann, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE LKB1; PROTEIN TSC1; TUBERIN; UNCLASSIFIED DRUG;

BENIGN TUMOR; COWDEN SYNDROME; DRUG TARGETING; GRAFT REJECTION; HAMARTOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHANGIOLEIOMYOMATOSIS; NEOPLASM; NONHUMAN; ORGAN TRANSPLANTATION; PEUTZ JEGHERS SYNDROME; REVIEW; TUBEROUS SCLEROSIS; TUMOR GROWTH;

EID: 80052963911     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2010.11.001     Document Type: Review

References (72)

1. Vanhaesebroeck B., Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000, 346:561-576.
2. Hresko R.C., Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005, 280:40406-40416.
3. Banaszynski L.A., Liu C.W., Wandless T.J. Characterization of the FKBP.rapamycin.FRB ternary complex. J Am Chem Soc 2005, 127:4715-4721.
4. Loranskaia T.I., Kabanova I.N., Klykova E.V. Effects of biologically active pectin-containing dietary supplement on gastroduodenal motility in patients with a functional dyspepsia. Vopr Pitan 2002, 71:31-33.
5. Jacinto E., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
6. Weichhart T., Saemann M.D. The multiple facets of mTOR in immunity. Trends Immunol 2009, 30:218-226.
7. Inoki K., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002, 4:648-657.
8. Weichhart T., et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008, 29:565-577.
9. Inoki K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
10. Nascimento E.B., Ouwens D.M. PRAS40: target or modulator of mTORC1 signalling and insulin action?. Arch Physiol Biochem 2009, 115:163-175.
11. Yang F.C., et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 2006, 116:2880-2891.
12. Sarbassov D.D., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
13. Krymskaya V.P., Goncharova E.A. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009, 8:403-413.
14. Inoki K., Corradetti M.N., Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005, 37:19-24.
15. Sampson J.R. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans 2009, 37:259-264.
16. El-Hashemite N., et al. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet 2003, 361:1348-1349.
17. Henske E.P., et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996, 59:400-406.
18. Roach E.S., Gomez M.R., Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998, 13:624-628.
19. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. Lancet 2008, 372:657-668.
20. Cook J.A., et al. A cross sectional study of renal involvement in tuberous sclerosis. J Med Genet 1996, 33:480-484.
21. Chan S.Y., Chan W.K. Huge renal angiomyolipomas in tuberous sclerosis complex. Nephrology (Carlton) 2005, 10:382-386.
22. Okada R.D., Platt M.A., Fleishman J. Chronic renal failure in patients with tuberous sclerosis. Association with renal cysts. Nephron 1982, 30:85-88.
23. Schillinger F., Montagnac R. Chronic renal failure and its treatment in tuberous sclerosis. Nephrol Dial Transplant 1996, 11:481-485.
24. Clarke A., et al. End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant 1999, 14:988-991.
25. Neumann H.P., et al. Tuberous sclerosis complex with end-stage renal failure. Nephrol Dial Transplant 1995, 10:349-353.
26. Shepherd C.W., et al. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991, 66:792-796.
27. Holmes G.L., Stafstrom C.E. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 2007, 48:617-630.
28. Chorianopoulos D., Stratakos G. Lymphangioleiomyomatosis and tuberous sclerosis complex. Lung 2008, 186:197-207.
29. McCormack F.X. Lymphangioleiomyomatosis: a clinical update. Chest 2008, 133:507-516.
30. Blumenthal G.M., Dennis P.A. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008, 16:1289-1300.
31. Kim J.J., Rini B.I., Hansel D.E. Von Hippel Lindau syndrome. Adv Exp Med Biol 2010, 685:228-249.
32. Wilson C., et al. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Hum Mol Genet 2005, 14:1839-1850.
33. Kenerson H., Dundon T.A., Yeung R.S. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 2005, 57:67-75.
34. Kenerson H.L., et al. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002, 62:5645-5650.
35. Lee L., et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005, 42:213-227.
36. Zeng L.H., et al. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63:444-453.
37. Ljungberg M.C., et al. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis Model Mech 2009, 2:389-398.
38. Podsypanina K., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 2001, 98:10320-10325.
39. Takahashi D.K., et al. Abnormal cortical cells and astrocytomas in the Eker rat model of tuberous sclerosis complex. Epilepsia 2004, 45:1525-1530.
40. Bissler J.J., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151.
41. Davies D.M., et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008, 358:200-203.
42. Herry I., et al. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007, 18:76-77.
43. Wienecke R., et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006, 48:e27-e29.
44. Krischock L., Beach R., Taylor J. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas. Arch Dis Child 2010, 95:391-392.
45. Higa F., et al. Malignant epithelioid angiomyolipoma in the kidney and liver of a patient with pulmonary lymphangioleiomyomatosis: lack of response to sirolimus. Intern Med 2009, 48:1821-1825.
46. Wolff N., et al. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol 2010, 28:e65-e68.
47. Motzer R.J., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
48. Motzer R.J., et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007, 25:3958-3964.
49. Pressey J.G., et al. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer 2010, 70:6566-6576.
50. Curatolo P., et al. Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J Child Neurol 2005, 20:318-325.
51. Franz D.N., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006, 59:490-498.
52. Koenig M.K., Butler I.J., Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008, 23:1238-1239.
53. Lam C., et al. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer 2010, 54:476-479.
54. Sparagana S.P., et al. Optic nerve tumor in tuberous sclerosis complex is not responsive to sirolimus. Pediatr Neurol 2010, 42:443-446.
55. Muncy J., Butler I.J., Koenig M.K. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol 2009, 24:477.
56. Marsh D.J., et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008, 5:357-361.
57. Benden C., et al. Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant 2009, 28:1-7.
58. Haidinger M., et al. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity. Transpl Int 2010, 89:1385-1390.
59. Tarasewicz A., et al. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc 2009, 41:3677-3682.
60. Hofbauer G.F., et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008, 159:473-475.
61. Johnson S.R. Lymphangioleiomyomatosis. Eur Respir J 2006, 27:1056-1065.
62. Egan J.J., Remund K.F., Corris P. Sirolimus for lymphangioleiomyomatosis lesions. N Engl J Med 2008, 358:1963-1964. [author reply 1964].
63. Sugimoto R., et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant 2008, 27:921-924.
64. Chen F., et al. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation. Ann Thorac Surg 2009, 87:e6-e7.
65. Ohara T., et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg 2008, 86:e7-e8.
66. Morton J.M., et al. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant 2008, 27:462-465.
67. Henriquez F., et al. Conversion to rapamycin in a renal transplant patient with von Hippel-Lindau disease: encouraging results-a case report. Transplant Proc 2008, 40:3115-3116.
68. Harrington L.S., Findlay G.M., Lamb R.F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 2005, 30:35-42.
69. Cho D.C., et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010, 16:3628-3638.
70. Workman P., et al. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010, 70:2146-2157.
71. Weichhart T., Saemann M.D. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 2008, 67(Suppl 3):iii70-iii74.
72. Janes M.R., et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010, 16:205-213.